Results 231 to 240 of about 18,195 (260)
Some of the next articles are maybe not open access.
Diarrhea associated with lansoprazole
Journal of Gastroenterology and Hepatology, 2003Abstract Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease. According to the manufacturer's package insert (TAP Pharmaceuticals, Lake Forest, IL, USA), the most common side‐effects are diarrhea, headache and abdominal pain, which occur in approximately 3% of patients and are ...
openaire +3 more sources
Lansoprazole, an antiulcerative drug
Acta Crystallographica Section C Crystal Structure Communications, 2000Lansoprazole, 2-({[3-methyl-4-(2,2,2-trifluroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole, C16H14F3N3O2S, is an antiulcerative agent. The molecules in the lattice are held together by intermolecular hydrogen bonds between the NH group of benzimidazole and the sulfinyl O atom.
G. Om Reddy +2 more
openaire +2 more sources
Lansoprazole: a cause of secretory diarrhea
The American Journal of Gastroenterology, 1998A case of severe diarrhea and hypergastrinemia after 6 wk of lansoprazole therapy is presented. This represents the only fully evaluated report of severe diarrhea due to lansoprazole and comes to the interesting conclusion that it was a secretory diarrhea likely due to lansoprazole and not a gastrinoma or another cause.
openaire +3 more sources
Pharmacokinetics and absolute bioavailability of lansoprazole
European Journal of Clinical Pharmacology, 1996In a crossover study 12 healthy volunteers received lansoprazole 15 mg or 30 mg orally, or 15 mg intravenously in randomized order as a single dose. Blood samples were taken and plasma levels of lansoprazole were determined using an HPLC method. The volunteers were phenotyped for the debrisoquine/sparteine and mephenytoin polymorphisms.The total ...
J Gerloff, H Barth, A Mignot, K Heintze
openaire +3 more sources
Lansoprazole: Alternate Day Dosing [PDF]
Hospital Pharmacy, 2003 Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses.
Joyce A. Generali, Dennis J. Cada
openaire +1 more source
Pediatric Drugs, 2003
Lansoprazole, a proton pump inhibitor, inactivates the H(+)/K(+)-ATPase pump in parietal cells, thereby suppressing basal and stimulated gastric acid secretion and increasing intragastric pH. After 8-12 weeks' treatment with lansoprazole, all children (n = 27) with esophagitis at baseline were healed (confirmed by endoscopy) and 76% of 62 evaluable ...
openaire +2 more sources
Lansoprazole, a proton pump inhibitor, inactivates the H(+)/K(+)-ATPase pump in parietal cells, thereby suppressing basal and stimulated gastric acid secretion and increasing intragastric pH. After 8-12 weeks' treatment with lansoprazole, all children (n = 27) with esophagitis at baseline were healed (confirmed by endoscopy) and 76% of 62 evaluable ...
openaire +2 more sources
Pharmacokinetic Interaction Between Lansoprazole and Theophylline
Therapeutic Drug Monitoring, 1995The pharmacokinetic interaction potential of the new proton-pump inhibitor lansoprazole and theophylline was assessed in a double-blind, two-period (13-day duration per period), multiple-dose crossover study in 14 healthy male volunteers. Lansoprazole 60 mg or placebo once daily was coadministered with anhydrous theophylline 200 mg four times daily ...
J H Cavanaugh +3 more
openaire +2 more sources
Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole
Alimentary Pharmacology & Therapeutics, 2004SummaryAim : To compare the pharmacokinetics and pharmacodynamics of lansoprazole 30 mg administered intravenously in 0.9% NaCl or in polyethylene glycol, or orally.Methods : Twenty‐nine subjects received lansoprazole orally on days 1–7 and intravenous lansoprazole in NaCl on days 8–14. Blood samples were collected on days 1, 7, 8 and 14. Fasting basal
J. S. Griffin +6 more
openaire +3 more sources
Possible Lansoprazole-Induced Eosinophilic Syndrome
Annals of Pharmacotherapy, 1998OBJECTIVE: To report a case of myalgia with eosinophilia related to lansoprazole administration. CASE SUMMARY: A 50-year-old white woman developed severe myalgia 1 week after starting lansoprazole. During the treatment course, the patient was also found to have eosinophilia.
John G. Gums +2 more
openaire +2 more sources
Lansoprazole: A Proton Pump Inhibitor
Annals of Pharmacotherapy, 1996OBJECTIVE: To summarize the published data on lansoprazole, a proton pump inhibitor approved by the Food and Drug Administration for use in the treatment of duodenal ulcer, erosive esophagitis, and pathologic hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
openaire +3 more sources